Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Interferon-based therapy reduces schizophrenia risk in patients with chronic hepatitis C

Key clinical point: Successful interferon (IFN)-based therapy is associated with a lower risk for schizophrenia among patients with chronic hepatitis C, particularly in those younger than 45 years.

Major finding: Following anti-hepatitis C virus therapy, the sustained virological response (SVR) group showed significantly lower 10-year cumulative incidence of schizophrenia vs non-SVR group (0.04% vs. 0.14%; P = .036). SVR group had a significantly lower risk for schizophrenia vs non-SVR group (adjusted hazard ratio, 5.89; P = .0200). Among patients younger than 45 years, the non-SVR group had a significantly higher risk for schizophrenia vs SVR group (hazard ratio, 14.78; P = .02).

Study details: A real-world Taiwanese cohort (T-COACH) study of 12,723 patients with chronic hepatitis C who received IFN-based therapy (SVR = 9,690 and non-SVR = 3,033).

Disclosures: The study was supported by Kaohsiung Medical University, Kaohsiung Medical University Research Center, and Kaohsiung Medical University Hospital. The authors declared no conflicts of interest.


Tsai PC et al. Open Forum Infect Dis. 2020 August 31. doi: 10.1093/ofid/ofaa397.